The commercially available compounds used were erastin (Selleckchem S7242), nutlin-3a (Sigma-Aldrich 444152), MDMX inhibitor NSC207895 (Calbiochem 444158), staurosporine (Selleckchem S1421), deferoxamine (Calbiochem 252750), MEL23 (InterBioscreen) (Herman et al. 2011 (link)), PPARα agonist (Pirinixic acid; Selleckchem S8029), PPARα antagonist (GW6471; Santa Cruz Biotechnology CAS 436159-64-7), PPARγ antagonist (GW9662; Santa Cruz Biotechnology CAS 22978-25-2), and DGAT1 inhibitor (Cayman Chemicals A-922500).
The following compounds were synthesized: IKE as in Larraufie et al. (2015) (link), fer-1 and RSL3 as in Dixon et al. (2012) (link), and FIN56 as in Shimada et al. (2016) (link).
All compounds were dissolved in DMSO (Sigma-Aldrich D8418). The fixed concentrations of compounds used was as follows (unless otherwise mentioned): 10 µM nutlin, 14 µM MEL23, 20 µM ferrostatin-1 (Fer-1), 90 µM deferoxamine (DFO), and 5 µM MDMX inhibitor.
The following compounds were synthesized: IKE as in Larraufie et al. (2015) (link), fer-1 and RSL3 as in Dixon et al. (2012) (link), and FIN56 as in Shimada et al. (2016) (link).
All compounds were dissolved in DMSO (Sigma-Aldrich D8418). The fixed concentrations of compounds used was as follows (unless otherwise mentioned): 10 µM nutlin, 14 µM MEL23, 20 µM ferrostatin-1 (Fer-1), 90 µM deferoxamine (DFO), and 5 µM MDMX inhibitor.